drugset / Trial / NCT07844954
Safety, Tolerability, and Pharmacokinetics of DM1001 Transdermal Patch in Healthy Chinese Participants
Phase 1
Not yet recruiting
66 enrolled
The Third Xiangya Hospital of Central South University
Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. · collab
Non-randomizedSequentialQuadruple-blindOther
Summary
This is a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of the DM1001 transdermal patch in healthy Chinese participants. Eligible participants will receive DM1001 according to the clinical trial protocol. Safety, tolerability, and pharmacokinetic assessments will be conducted at prespecified time points during the study. The study is intended to provide initial information on the safety, tolerability, and pharmacokinetic characteristics of DM1001 in humans.
Timeline
- Start
- 2026-09-30
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pramipexole | Unknown | 1.5 mg | Oral |
| Comparator | Pramipexole | Unknown | 2.8 mg | Other |
| Comparator | Pramipexole | Unknown | 5.6 mg | Other |
| Comparator | Pramipexole | Unknown | 11.2 mg | Other |
Indications
No indication recorded.